Efficacy and Safety of Adjuvant Single-Fraction Radiotherapy for Excised Keloids: A Prospective Randomized Controlled Trial
In brief
13 Gy radiation limited keloid recurrence to 7% at 12 months
In a randomized trial of 88 patients, keloids recurred within 12 months in 6.9% of those given 13 Gy after excision, compared with 17.2% after 11 Gy and 23.3% after 9 Gy. The 13 Gy group also had better scar scores, supporting higher doses especially at high-tension sites, but the best dose for lower-tension sites remains uncertain.
- Journal
- International journal of radiation oncology, biology, physics (Q1)
- Published
- 15 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Roan TL, Chang DH, Kuo DY, Shueng PW, Lin YF, Tien HJ, et al.
- PMID
- 43035183
- DOI
- 10.1016/j.ijrobp.2026.10.054
Why clinicians should know about it
- Picked for Radiology, Radiation Oncology, Nuclear Medicine, Medical Physics and Imaging (paper of the day, 18 November 2026): 13 Gy single-fraction regimen superior local control
- Picked for Radiation Oncology (paper of the day, 17 November 2026): Single-fraction RT dose-response trial
Abstract
PURPOSE: While fractionated postoperative radiotherapy regimens for keloids are well established, the optimal dose for single-fraction delivery remains to be definitively defined. This prospective, randomized trial characterized the dose-response relationship of single-fraction radiotherapy and evaluated the impact of local tissue tension on treatment outcomes. METHODS AND MATERIALS: Eighty-eight patients with surgically excised keloids were randomized to receive a single fraction of electron beam radiotherapy at 9 Gy (n = 30), 11 Gy (n = 29), and 13 Gy (n = 29) within 24 hours of surgery. The primary endpoint was 12-month local control. Secondary endpoints included objective scar assessment using the modified Vancouver Scar Scale (mVSS) and patient-reported quality of life via Skindex-16. RESULTS: At 12 months, recurrence rates were 23.3%, 17.2%, and 6.9% for the 9, 11, and 13 Gy groups, respectively. In multivariable logistic regression, the 9 Gy dose was an independent predictor of recurrence relative to 13 Gy (OR, 5.7; 95% CI, 1.0-32.3; P = .046). Longitudinal analysis using generalized estimating equations demonstrated superior objective scar outcomes in the 13 Gy group compared with 9 Gy (P < .001) and 11 Gy (P < .001). Receiver operating characteristic analysis identified an mVSS score ≥ 7 as a highly accurate predictor of recurrence (AUC = 0.93). CONCLUSIONS: A 13 Gy single-fraction postoperative regimen provided superior local control and cosmetic outcomes compared with 9 Gy, particularly at high-tension anatomic sites. These findings support a risk-stratified, tension-based dosing strategy, wherein dose de-escalation may be considered at low-tension sites without compromising local control.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.